MIRIAM MERNEIGH: Open Payments
NPI 1669028320 · BURLESON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,872 in 111 payments from 22 companies in 2025. Trend: 2023 $1,300 · 2024 $1,841 · 2025 $2,872
Food & beverage: $2,872
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 32 | $717 |
| AstraZeneca Pharmaceuticals LP | 20 | $507 |
| GENZYME CORPORATION | 8 | $339 |
| Insmed, Inc. | 14 | $188 |
| Verona Pharma, Inc. | 4 | $184 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $143 |
| ANI Pharmaceuticals, Inc. | 3 | $139 |
| Regeneron Healthcare Solutions, Inc. | 1 | $117 |
| Viatris Specialty LLC | 5 | $107 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70 |
Products named: DUPIXENT, FASENRA, NUCALA, AREXVY, TRELEGY ELLIPTA, Ohtuvayre, Arikayce, LUMRYZ.
Industry payments across TX — which companies pay providers there.
